TScan Therapeutics, Inc.’s TCRX share price has dipped by 5.81%, which has investors questioning if this is right time to buy ...

Granite Bio AG, a clinical-stage immunology company, has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis ...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...

OmniAb, Inc. today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down ...

Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to sell.

Gotwals brings over 30 years of biopharmaceutical experience, including roles at Novartis Institutes for BioMedical Research and Biogen Idec, and currently serves as a partner at Red Sky Partners.

Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, becoming the latest pharmaceutical company to shift operations to the ...

Roche and the pharmaceutical industry as a whole are grappling with the effects of President Donald Trump’s tariffs on imports to the U.S. Drugmaker Novartis’ also plans to spend $23 billion ...

Philip Gotwals, Ph.D. and Steve Crouse bring strategic and operational experience in business development and global tools and technology “We’re delighted to welcome Phil and Steve to our ...